PSNL Personalis Inc.

20.17
+0.29  (+1%)
Previous Close 19.88
Open 20
52 Week Low 4.27
52 Week High 22.9997
Market Cap $643,111,495
Shares 31,884,556
Float 19,630,288
Enterprise Value $539,971,973
Volume 518,223
Av. Daily Volume 347,462
Stock charts supplied by TradingView

Latest News

  1. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.

    About Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.

    About Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

    View Full Article Hide Full Article
  2. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share. Gross proceeds to Personalis from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses.

    In addition, the underwriters have been granted a 30-day option to purchase up to an additional 986,842 shares of common stock from a selling stockholder on the same terms and conditions. Personalis will not receive any proceeds from any sale of shares by the selling stockholder.

    BofA Securities, Citigroup…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share. Gross proceeds to Personalis from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses.

    In addition, the underwriters have been granted a 30-day option to purchase up to an additional 986,842 shares of common stock from a selling stockholder on the same terms and conditions. Personalis will not receive any proceeds from any sale of shares by the selling stockholder.

    BofA Securities, Citigroup and Cowen are acting as joint book-running managers. BTIG, Needham & Company and Oppenheimer & Co. are acting as co-managers.

    A shelf registration statement relating to the shares being sold in this offering was filed with the U.S. Securities and Exchange Commission on July 2, 2020, and was declared effective on July 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and are available for free on the SEC's website located at http://www.sec.gov. When available, electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from BofA Securities, Inc., Attention: Prospectus Department, NC1‐004‐03‐43, 200 North College Street, 3rd floor, Charlotte, NC 28255‐0001, or by emailing ; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 631‐274‐2806.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Personalis, Inc.

    Personalis, Inc. is a growing population sequencing and cancer genomics company, with a continuing focus on scale, efficiency and quality. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis® Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited.

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements relating to Personalis' expectations regarding the underwritten public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. Personalis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, the fact that completion of the underwritten public offering is subject to the satisfaction of customary closing conditions. Risks and uncertainties relating to Personalis and its business can be found in the "Risk Factors" section of Personalis' Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 6, 2020, in the preliminary prospectus supplement related to the public offering filed with the SEC on August 11, 2020, and in the final prospectus supplement related to the public offering to be filed with the SEC on or about August 12, 2020. Personalis undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Personalis' expectations, except as required by law.

    View Full Article Hide Full Article
  3. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $100 million of its common stock. In addition, Personalis expects the underwriters to be granted a 30-day option to purchase up to an additional $15 million of common stock from a selling stockholder on the same terms and conditions. Personalis will not receive any proceeds from any sale of shares by the selling stockholder.

    The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

    BofA Securities, Citigroup and Cowen are acting as joint book-running…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $100 million of its common stock. In addition, Personalis expects the underwriters to be granted a 30-day option to purchase up to an additional $15 million of common stock from a selling stockholder on the same terms and conditions. Personalis will not receive any proceeds from any sale of shares by the selling stockholder.

    The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

    BofA Securities, Citigroup and Cowen are acting as joint book-running managers. BTIG, Needham & Company and Oppenheimer & Co. are acting as co-managers.

    A shelf registration statement relating to the shares being sold in this offering was filed with the U.S. Securities and Exchange Commission on July 2, 2020, and was declared effective on July 10, 2020. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC's website located at http://www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained from BofA Securities, Inc., Attention: Prospectus Department, NC1‐004‐03‐43, 200 North College Street, 3rd floor, Charlotte, NC 28255‐0001, or by emailing ; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 631‐274‐2806.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Personalis, Inc.

    Personalis, Inc. is a growing population sequencing and cancer genomics company, with a continuing focus on scale, efficiency and quality. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis® Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited.

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements relating to Personalis' expectations regarding the proposed public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. Personalis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions, the risk that the proposed public offering will not be consummated on the terms or in the amounts contemplated or otherwise, and the satisfaction of customary closing conditions related to the proposed public offering. Risks and uncertainties relating to Personalis and its business can be found in the "Risk Factors" section of Personalis' Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 6, 2020, and in the preliminary prospectus supplement related to the proposed public offering filed with the SEC on August 11, 2020. Personalis undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Personalis' expectations, except as required by law.

    View Full Article Hide Full Article
  4. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020.

    Second Quarter Highlights

    • Reported record revenues of $19.5 million in the second quarter of 2020 versus $15.8 million in the second quarter of 2019, an increase of 23%
    • A total of 32 customers have placed orders for NeXT as of June 30, 2020, with 6 of those customers placing their first orders in the second quarter of 2020
    • Announced a collaboration with Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare disease
    • Announced expansion plans into China along with a partnership with Berry Genomics, who will provide services and support to Personalis…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020.

    Second Quarter Highlights

    • Reported record revenues of $19.5 million in the second quarter of 2020 versus $15.8 million in the second quarter of 2019, an increase of 23%
    • A total of 32 customers have placed orders for NeXT as of June 30, 2020, with 6 of those customers placing their first orders in the second quarter of 2020
    • Announced a collaboration with Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare disease
    • Announced expansion plans into China along with a partnership with Berry Genomics, who will provide services and support to Personalis
    • Achieved milestone of completing the 75,000th whole human genome sequenced under the contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP)

    "I'm proud to say that we were able to report record revenues once again this quarter, with our team delivering strong execution across both our population sequencing and biopharma businesses, despite the impact from the COVID-19 pandemic, and we continued to see strong ordering levels from both our existing and new customers," said John West, Chief Executive Officer. "In addition, our recently announced liquid biopsy product will be available to order immediately."

    Second Quarter 2020 Financial Results

    Revenues were $19.5 million in the three months ended June 30, 2020, up 23.2% from $15.8 million in the same period of the prior year. In the second quarter, the VA MVP accounted for $14.8 million of our total revenues, and the remaining $4.7 million was from biopharmaceutical and all other customers.

    Gross margin was 24.0% for the three months ended June 30, 2020, compared with 37.3% in the same period of the prior year.

    Operating expenses were $14.2 million for the three months ended June 30, 2020, compared with $10.0 million in the same period of the prior year.

    Net loss was $9.3 million for the three months ended June 30, 2020 and net loss per share was $0.29 based on a weighted-average basic and diluted share count of 31.7 million, compared with a net loss of $5.9 million and a net loss per share of $0.89 based on a weighted-average basic and diluted share count of 6.6 million in the same period of the prior year.

    Cash, cash equivalents, and short-term investments were $105.2 million as of June 30, 2020.

    Outlook and COVID-19

    Due to continued uncertainty surrounding the COVID-19 pandemic, Personalis will not provide an outlook for fiscal 2020 at this time and will plan to give an update during its third quarter earnings announcement and press release, to the extent practicable, based on available information at that time.

    Webcast and Conference Call Information

    Personalis will host a conference call to discuss the second quarter financial results after market close on Thursday, August 6, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live over the phone (866) 220-8061 for U.S. callers or (470) 495-9168 for international callers, using conference ID: 4682918. The live webinar can be accessed at https://investors.personalis.com.

    About Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "hope," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers; the launch of our new liquid biopsy product and customer adoption of such new products; the timing of tissue and blood sample receipts from customers, which can materially impact revenue quarter over quarter and year over year; whether orders for the NeXT platform® and revenues from biopharmaceutical customers will increase; the success of our collaborations and partnerships, including with Sarepta Therapeutics and Berry Genomics; the success of our international expansion plans; the evolution of cancer therapies and market adoption of our services; our expectations regarding future performance; and the COVID-19 pandemic, which may significantly impact our business and operations and the business and operations of our customers. In addition, other potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the period ended June 30, 2020, that will be filed following this earnings release. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

    PERSONALIS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

    (in thousands, except share and per share data)

     

     

     

    Three Months Ended

     

     

    Six Months Ended

     

     

     

    June 30,

     

     

    June 30,

     

     

     

    2020

     

     

    2019

     

     

    2020

     

     

    2019

     

    Revenues

     

    $

    19,495

     

     

    $

    15,825

     

     

    $

    38,656

     

     

    $

    29,900

     

    Costs and expenses

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Costs of revenues

     

     

    14,823

     

     

     

    9,923

     

     

     

    29,945

     

     

     

    20,014

     

    Research and development

     

     

    6,465

     

     

     

    4,497

     

     

     

    12,855

     

     

     

    9,742

     

    Selling, general and administrative

     

     

    7,705

     

     

     

    5,466

     

     

     

    14,979

     

     

     

    9,636

     

    Total costs and expenses

     

     

    28,993

     

     

     

    19,886

     

     

     

    57,779

     

     

     

    39,392

     

    Loss from operations

     

     

    (9,498

    )

     

     

    (4,061

    )

     

     

    (19,123

    )

     

     

    (9,492

    )

    Interest income

     

     

    246

     

     

     

    200

     

     

     

    756

     

     

     

    284

     

    Interest expense

     

     

     

     

     

    (745

    )

     

     

    (2

    )

     

     

    (929

    )

    Other income (expense), net

     

     

    1

     

     

     

    (1,261

    )

     

     

    9

     

     

     

    (1,413

    )

    Loss before income taxes

     

     

    (9,251

    )

     

     

    (5,867

    )

     

     

    (18,360

    )

     

     

    (11,550

    )

    Provision for income taxes

     

     

    (4

    )

     

     

    (2

    )

     

     

    (34

    )

     

     

    (4

    )

    Net loss

     

    $

    (9,255

    )

     

    $

    (5,869

    )

     

    $

    (18,394

    )

     

    $

    (11,554

    )

    Net loss per share, basic and diluted

     

    $

    (0.29

    )

     

    $

    (0.89

    )

     

    $

    (0.58

    )

     

    $

    (2.38

    )

    Weighted-average shares outstanding, basic and diluted

     

     

    31,731,628

     

     

     

    6,597,007

     

     

     

    31,538,329

     

     

     

    4,853,325

     

    PERSONALIS, INC.

    SUPPLEMENTAL REVENUE INFORMATION (unaudited)

    (in thousands)

     

     

     

    Three Months Ended June 30,

     

     

    Six Months Ended June 30,

     

     

     

    2020

     

     

    2019

     

     

    2020

     

     

    2019

     

    VA MVP

     

    $

    14,750

     

     

    $

    8,536

     

     

    $

    29,506

     

     

    $

    16,879

     

    All other customers

     

     

    4,745

     

     

     

    7,289

     

     

     

    9,150

     

     

     

    13,021

     

    Total

     

    $

    19,495

     

     

    $

    15,825

     

     

    $

    38,656

     

     

    $

    29,900

     

    PERSONALIS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

    (in thousands, except share and per share data)

     

     

     

    June 30,

     

     

    December 31,

     

     

     

    2020

     

     

    2019

     

    Assets

     

     

     

     

     

     

     

     

    Current assets

     

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    25,042

     

     

    $

    55,046

     

    Short-term investments

     

     

    80,191

     

     

     

    73,243

     

    Accounts receivable, net

     

     

    5,375

     

     

     

    3,300

     

    Inventory and other deferred costs

     

     

    6,524

     

     

     

    4,606

     

    Prepaid expenses and other current assets

     

     

    2,989

     

     

     

    3,383

     

    Total current assets

     

     

    120,121

     

     

     

    139,578

     

    Property and equipment, net

     

     

    12,650

     

     

     

    14,106

     

    Operating lease right-of-use assets

     

     

    10,991

     

     

     

    1,845

     

    Other long-term assets

     

     

    1,760

     

     

     

    1,762

     

    Total assets

     

    $

    145,522

     

     

    $

    157,291

     

    Liabilities and Stockholders' Equity

     

     

     

     

     

     

     

     

    Current liabilities

     

     

     

     

     

     

     

     

    Accounts payable

     

    $

    7,491

     

     

    $

    7,337

     

    Accrued and other current liabilities

     

     

    6,594

     

     

     

    6,648

     

    Contract liabilities

     

     

    28,952

     

     

     

    35,977

     

    Total current liabilities

     

     

    43,037

     

     

     

    49,962

     

    Long-term operating lease liabilities

     

     

    9,233

     

     

     

    639

     

    Other long-term liabilities

     

     

    129

     

     

     

     

    Total liabilities

     

     

    52,399

     

     

     

    50,601

     

    Commitments and Contingencies

     

     

     

     

     

     

     

     

    Stockholders' equity

     

     

     

     

     

     

     

     

    Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued

     

     

     

     

     

     

    Common stock, $0.0001 par value — 200,000,000 shares authorized; 31,872,122 and 31,243,029 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively

     

     

    3

     

     

     

    3

     

    Additional paid-in capital

     

     

    251,997

     

     

     

    247,282

     

    Accumulated other comprehensive income (loss)

     

     

    106

     

     

     

    (6

    )

    Accumulated deficit

     

     

    (158,983

    )

     

     

    (140,589

    )

    Total stockholders' equity

     

     

    93,123

     

     

     

    106,690

     

    Total liabilities and stockholders' equity

     

    $

    145,522

     

     

    $

    157,291

     

     

    View Full Article Hide Full Article
  5. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. NeXT Liquid Biopsy, paired with Personalis' leading ImmunoID NeXT™ tissue profiling platform, enables a more comprehensive immuno-genomics view of the tumor that can now be monitored over time from blood samples. NeXT Liquid Biopsy monitors over twenty times more genes than the majority of liquid biopsy cancer panels on the market today. These capabilities will help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. NeXT Liquid Biopsy, paired with Personalis' leading ImmunoID NeXT™ tissue profiling platform, enables a more comprehensive immuno-genomics view of the tumor that can now be monitored over time from blood samples. NeXT Liquid Biopsy monitors over twenty times more genes than the majority of liquid biopsy cancer panels on the market today. These capabilities will help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development of next-generation cancer therapies.

    Personalis CEO, John West, said, "Solid tumor biopsies and liquid biopsies complement each other, and it is important to utilize both in cancer research. Solid tumor biopsies can yield information about mutations, gene expression, the tumor microenvironment, and immune cells that have infiltrated the tumor, while liquid biopsies can track mutations and detect new mutations over time in response to treatment. By combining NeXT Liquid Biopsy with ImmunoID NeXT, researchers now have a powerful tool to address tumor heterogeneity, longitudinally monitor clonal and subclonal dynamics, identify acquired resistance mechanisms, and access key areas of tumor biology not typically included in targeted liquid biopsy panels. We strongly believe this will provide a powerful framework for translational research, and the development of next-generation cancer therapeutics to overcome therapy resistance and cancer progression."

    Mr. West added, "Through our collaborations program, we are encouraged by our partners' response to NeXT Liquid Biopsy. NeXT Liquid Biopsy represents a new capability in the market and we look forward to working closely with our first customers. This is just the first step in Personalis' liquid biopsy product portfolio and we are excited for further developments in this area."

    NeXT Liquid Biopsy is immediately available for order.

    About Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

    Forward-Looking Statements

    This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts, including, for example, statements relating to the capabilities, availability or benefits of NeXT Liquid Biopsy, potential advancement of or growth opportunities for Personalis' business, expansion of Personalis' market presence in immuno-oncology, the company's services for the VA Million Veterans Program, and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis' filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

    View Full Article Hide Full Article
View All Personalis Inc. News